Stacey A. Cohen, MD, and Daniel H. Ahn, DO, discuss the role of circulating tumor DNA (ctDNA) as a biomarker in colorectal cancer and provide clinical insights on screening modalities.
Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases
Aspirin led to a median disease-free survival of 1.16 years vs 1.35 years with placebo in patients with colorectal cancer liver metastases.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Adverse Sexual Health Outcomes Appear More Likely in Women With CRC
In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.
Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC
As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.
Genomic Alterations May Cause Resistance to Sotorasib KRAS G12C+ CRC Combo
Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.